Tempe-based Clinical Research Advantage, a community-based network of clinical trial sites, has been named Best Clinical Trial Site Network by the World Vaccine Congress. The award was announced at the 2012 Vaccine Industry Excellence Awards in Washington, D.C. on April 11th. The VIE Awards celebrate the leaders, innovators and pioneers in the vaccine industry. Clinical Research Advantage also received second place for Best Clinical Trial Site.

“We are honored to win this prestigious award,” said Mark Hanley, CEO of Clinical Research Advantage. “The key to CRA’s success has been the development of research offices within community physician practices. We take pride in partnering with these established practices to provide rapid, successful enrollment that expedites the process of bringing vaccines to market.”

Casey Orvin, CRA’s Vice President of Business Development was on hand to accept the award in Washington, D.C. “It is with great honor that we accept the award for Best Clinical Trial Site Network. We are grateful to all the pharmaceutical sponsors and CROs who trust our sites and staff, time and time again, to successfully enroll in their vaccine studies. We have been fortunate, for the last several years, to be the leader in providing high quality data and rapidly enrolling sites to the vaccine industry,” said Orvin.

The Vaccine Industry Excellence Award nominees are voted on by an independent judging panel, comprised of senior industry representatives from public health organizations, non-governmental organizations, academic and research institutes, industry experts and affiliate member associations, pharmaceutical, biotech, global consultancies and press affiliates.

For more information on Clinical Research Advantage, visit Clinical Research Advantage’s website at crastudies.com.